Repository logo
 

Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients.

Published version

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Women with ovarian cancer have limited therapy options, with immunotherapy being unsatisfactory for a large group of patients. Tumor cells spread from the ovary or the fallopian tube into the abdominal cavity, which is commonly accompanied with massive ascites production. The ascites represents a unique peritoneal liquid tumor microenvironment with the presence of both tumor and immune cells, including cytotoxic lymphocytes. We characterized lymphocytes in ascites from patients with high-grade serous ovarian cancer. Our data reveal the presence of NK and CD8+ T lymphocytes expressing CD103 and CD49a, which are markers of tissue residency. Moreover, these cells express high levels of the inhibitory NKG2A receptor, with the highest expression level detected on tissue-resident NK cells. Lymphocytes with these features were also present at the primary tumor site. Functional assays showed that tissue-resident NK cells in ascites are highly responsive towards ovarian tumor cells. Similar results were observed in an in vivo mouse model, in which tissue-resident NK and CD8+ T cells were detected in the peritoneal fluid upon tumor growth. Together, our data reveal the presence of highly functional lymphocyte populations that may be targeted to improve immunotherapy for patients with ovarian cancer.

Description

Peer reviewed: True


Funder: Cambridge NIHR BRC Cell Phenotyping Hub


Funder: Swedish Society for Medical Research


Funder: University of Milan


Funder: AstraZeneca-MedImmune-Cambridge PhD fellowship


Funder: Experimental Medicine at the University of Milan


Funder: Cancer Research UK


Funder: Cancer Research UK Cambridge Centre


Funder: Mark Foundation Institute for Integrated Cancer Medicine

Journal Title

Cancers (Basel)

Conference Name

Journal ISSN

2072-6694
2072-6694

Volume Title

15

Publisher

MDPI

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Wellbeing of Women (RG2331)
Cancer Research UK (A25117)
Cancer Research UK (22905)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Cancer Research UK (15601)
Wellcome Trust (094073/Z/10/Z)
This research was funded by a Research Award from the Wellbeing of Women (RG2331; F.C., E.B., J.B.), a Wellcome Investigator Award (094073/Z/10/Z; F.C.), the Cambridge NIHR BRC Cell Phenotyping Hub (F.C.), the Swedish cancer foundation society (20 0226 P 01 H; E.B. and CAN 2018/384; K.S.), the Swedish research council (2019-06328; E.B.), the Swedish Society for Medical Research (E.B.), the Swedish Society for Medicine (SLS-881711; E.B.), the Assar Gabrielsson founda- tion (BRG20-06; E.B.), Swedish state under the agreement between the Swedish government and the county council, the ALF agreement (ALFGBG-965552; K.S.), Italian Ministry of Health (Bando Ri- cerca Finalizzata PE-2016-02363915, D.M.), Associazione Italiana per la Ricerca sul Cancro (IG 14687; D.M.), Intramural research and clinical funding programs of Humanitas Research Hospital (5 X 1000; D.M.) and University of Milan (D.M.). O.H. was supported by a AstraZeneca-MedImmune- Cambridge PhD fellowship. V.C. is a recipient of a competitive fellowship awarded from the Ph.D. program of Experimental Medicine at the University of Milan.